Atara Biotherapeutics (ATRA) Change in Receivables (2020 - 2026)

Atara Biotherapeutics has reported Change in Receivables for 7 years, with the latest figure at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 116.95% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$8.9 million (up 67.08% YoY), and the FY2025 full-year result was -$229000.0, up 99.3% from the prior year.
• Change in Receivables for Q1 2026 stood at -$1.3 million, down from -$660000.0 in the prior quarter.
• The five-year high for Change in Receivables was $40.0 million in Q4 2022, with the low at -$39.8 million in Q1 2023.
• Historically, Change in Receivables has averaged -$58000.0 across 5 years, with a median of -$318000.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Receivables jumped 3953.96% — and 2024, when it sank 30474.55%.
• Atara Biotherapeutics' Change in Receivables stood at $40.0 million in 2022, then retreated by 15.08% to $33.9 million in 2023, then sank by 99.57% to $147000.0 in 2024, then tumbled by 548.98% to -$660000.0 in 2025, then tumbled by 89.85% to -$1.3 million in 2026.
• The last three Change in Receivables figures came in at -$1.3 million (Q1 2026), -$660000.0 (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.